Vanguard Group
ADIL

Vanguard Group’s Adial Pharmaceuticals ADIL Stock Holding History

Vanguard Group’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$34.3K Hold
6,241
– – ﹤0.01% 4277
2025
Q3 		$55.2K Buy
6,241
+5,715
+1,087% +$55.7K ﹤0.01% 4289
2025
Q2 		$3.97K Hold
526
– – ﹤0.01% 4267
2025
Q1 		$8.34K Buy
+526
New +$10.9K ﹤0.01% 4260
2023
Q3 		– Sell
-325
Closed -$42.3K – 4539
2023
Q2 		$42.3K Hold
325
– – ﹤0.01% 4475
2023
Q1 		$71.2K Sell
325
-441
-58% -$107K ﹤0.01% 4433
2022
Q4 		$103K Sell
766
-221
-22% -$38.7K ﹤0.01% 4388
2022
Q3 		$216K Buy
987
+42
+4% +$18.9K ﹤0.01% 4404
2022
Q2 		$792K Hold
945
– – ﹤0.01% 4158
2022
Q1 		$1.19M Hold
945
– – ﹤0.01% 4156
2021
Q4 		$1.59M Sell
945
-6
-0.6% -$11.8K ﹤0.01% 4123
2021
Q3 		$2.55M Buy
951
+15
+2% +$31.4K ﹤0.01% 3986
2021
Q2 		$1.49M Buy
936
+592
+172% +$900K ﹤0.01% 4050
2021
Q1 		$520K Buy
344
+29
+9% +$43.8K ﹤0.01% 4129
2020
Q4 		$335K Hold
315
– – ﹤0.01% 4024
2020
Q3 		$439K Sell
315
-138
-30% -$129K ﹤0.01% 3836
2020
Q2 		$393K Hold
453
– – ﹤0.01% 3820
2020
Q1 		$368K Hold
453
– – ﹤0.01% 3734
2019
Q4 		$682K Hold
453
– – ﹤0.01% 3730
2019
Q3 		$424K Sell
453
-17
-4% -$18.1K ﹤0.01% 3848
2019
Q2 		$494K Sell
470
-16
-3% -$23.9K ﹤0.01% 3829
2019
Q1 		$1.04M Buy
486
+424
+684% +$1.26M ﹤0.01% 3620
2018
Q4 		$200K Buy
+62
New +$99.1K ﹤0.01% 3904

Other funds holding ADIL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

Vanguard Group's ADIL Position: Q4 2025 in Review

Vanguard Group held its Adial Pharmaceuticals (ADIL) position steady in Q4 2025 at 6,241 shares worth $34.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4277.

Vanguard Group first reported a position in ADIL in Q4 2018 and has held it in 23 quarters since. The position peaked at $2.55M in Q3 2021. 21 funds tracked by Wall St. Rank hold ADIL as of Q4 2025.

  • Vanguard Group held 6,241 shares of Adial Pharmaceuticals worth $34.3K as of Q4 2025.
  • Vanguard Group left its Adial Pharmaceuticals share count unchanged in Q4 2025.
  • Adial Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4277 holding.
  • Vanguard Group first reported a position in Adial Pharmaceuticals in Q4 2018 and has held it in 23 quarters since.
  • Vanguard Group's Adial Pharmaceuticals position peaked at $2.55M in Q3 2021.
  • 21 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.